WallStreetZenWallStreetZen

NASDAQ: VIRX
Viracta Therapeutics Inc Stock Ownership - Who owns Viracta Therapeutics?

OverviewForecastEarningsDividendOwnership

Insider buying vs selling

Have Viracta Therapeutics Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Daniel R. ChevallardCFO and COO2024-02-273,405$0.73
$2.49kSell
Mark RotheraPresident and CEO2023-12-0147,906$0.49
$23.62kBuy
Mark RotheraPresident and CEO2023-11-3052,094$0.49
$25.73kBuy
Daniel R. ChevallardCFO and COO2023-11-283,720$0.50
$1.86kSell
Daniel R. ChevallardCFO and COO2023-08-283,512$1.45
$5.09kSell
Daniel R. ChevallardCFO and COO2023-05-253,635$1.42
$5.16kSell

1 of 1

VIRX insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when VIRX insiders and whales buy or sell their stock.

VIRX Shareholders

What type of owners hold Viracta Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Ryan D. Drant110.71%43,478,774$37.26MInsider
Krishna Kittu Kolluri97.98%38,478,774$32.98MInsider
Patrick J. Kerins97.98%38,478,774$32.98MInsider
Forest Baskett97.98%38,478,774$32.98MInsider
Alta Biopharma Partners Iii LP40.54%15,919,950$13.64MInsider
Bay City Capital LLC26.02%10,217,502$8.76MInsider
Aisling Capital Iv LP25.72%10,100,000$8.66MInsider
Jonathan S. Leff21.92%8,608,166$7.38MInsider
Amoon 2 Fund Limited Partnership18.82%7,392,237$6.34MInsider
Dominique Semon13.82%5,429,146$4.65MInsider

1 of 3

VIRX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
VIRX3.63%96.37%Net BuyingNet Selling
OKYO0.15%99.85%Net Buying
TARA11.95%88.05%Net Selling
VAXX4.14%95.86%Net Buying
BCTX15.42%12.34%
View Top Biotech Stocks

Viracta Therapeutics Stock Ownership FAQ

Who owns Viracta Therapeutics?

Viracta Therapeutics (NASDAQ: VIRX) is owned by 24.83% institutional shareholders, 659.33% Viracta Therapeutics insiders, and 0.00% retail investors. Ryan D. Drant is the largest individual Viracta Therapeutics shareholder, owning 43.48M shares representing 110.71% of the company. Ryan D. Drant's Viracta Therapeutics shares are currently valued at $38.26M.

If you're new to stock investing, here's how to buy Viracta Therapeutics stock.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.